secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-02-08T23:59:59+00:00
Accession:  0001564590-23-001611
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Q4 net loss $0.26/shr; cash $155M; NASH study data expected Q2 2023
--------------------------------------------------------------------------

- Net loss $19.6M ($0.26/shr) for Q4 2022 vs $12.4M ($0.16/shr) in Q4 2021; R&D expense rose to $16.2M.
- Full-year 2022 net loss $68.9M ($0.90/shr) vs $55.0M ($0.71/shr) in 2021; cash $155M (down from $202M).
- Enrollment completed for Phase 2b VOYAGE study of VK2809 in NASH/fibrosis; topline data expected Q2 2023.
- Phase 1 trial of dual GLP-1/GIP agonist VK2735 ongoing; initial data expected Q1 2023.
- Phase 1b study of VK0214 in X-ALD enrolling; data expected H2 2023; cash runway beyond key milestones.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/0001564590-23-001611-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459023001611/vktx-8k_20230208.htm
  HTML page:      https://secwatch.observer/filing/0001564590-23-001611

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer